Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,792 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Yang F, et al. Cancer Res. 2011 Aug 15;71(16):5512-21. doi: 10.1158/0008-5472.CAN-10-2614. Epub 2011 Jul 1. Cancer Res. 2011. PMID: 21724587 Free PMC article.
A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis.
Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, Scott KL, Edwards JR, Liang H, Heffernan TP, Piwnica-Worms H. Powell E, et al. Among authors: yang f. NPJ Breast Cancer. 2018 Apr 30;4:9. doi: 10.1038/s41523-018-0062-x. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 29736411 Free PMC article.
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. Ai D, et al. Among authors: yang f. Mod Pathol. 2021 Apr;34(4):710-719. doi: 10.1038/s41379-020-00692-8. Epub 2020 Oct 3. Mod Pathol. 2021. PMID: 33011748 Free article.
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. Pairawan S, et al. Among authors: yang f. Breast Cancer Res. 2021 Mar 4;23(1):29. doi: 10.1186/s13058-021-01406-x. Breast Cancer Res. 2021. PMID: 33663585 Free PMC article.
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. Fujii T, et al. Among authors: yang f. Breast Cancer Res Treat. 2021 Sep;189(2):455-461. doi: 10.1007/s10549-021-06276-7. Epub 2021 Jun 15. Breast Cancer Res Treat. 2021. PMID: 34131830
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Yam C, et al. Among authors: yang f. Clin Cancer Res. 2021 Oct 1;27(19):5365-5375. doi: 10.1158/1078-0432.CCR-21-0144. Clin Cancer Res. 2021. PMID: 34253579 Free PMC article.
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF; NCI PDXNet Consortium; Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Sun H, et al. Nat Commun. 2021 Aug 24;12(1):5086. doi: 10.1038/s41467-021-25177-3. Nat Commun. 2021. PMID: 34429404 Free PMC article.
Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Sun X, et al. Among authors: yang f. Mod Pathol. 2022 May;35(5):601-608. doi: 10.1038/s41379-021-00973-w. Epub 2021 Nov 27. Mod Pathol. 2022. PMID: 34839351 Free article.
21,792 results
You have reached the last available page of results. Please see the User Guide for more information.